Mass Tort brief
Mass Tort & Product Liability: Docket Trends, HIV Drug Suits, and Contraceptive Claims
Multidistrict litigation centralizes major product liability dockets as pharmaceutical injury claims and class actions advance in federal courts.
Mass Tort
Gilead narrowed state-law claims in its HIV drug injury litigation — but core negligence suits over delayed safer drug releases move forward to trial.
BackgroundPlaintiffs allege Gilead delayed marketing a safer alternative drug formulation called TAF to maximize profits on older TDF medications like Viread and Truvada. Thousands of HIV patients claim the older formulation caused avoidable kidney damage and bone density loss.
- The court dismissed select state failure-to-warn and design defect counts against Gilead Sciences, narrowing the formal scope of state law claims.
- Core negligence allegations claiming Gilead intentionally delayed safer TAF drug formulations remain active and are now cleared to advance toward trial.
- Thousands of HIV patients continue to pursue personal injury compensation over TDF-related kidney and bone injuries in coordinated state and federal filings.
Mass Tort
Depo-Provera brain tumor suits are heading toward central MDL consolidation — Pfizer faces a rapidly expanding product liability threat over its long-standing contraceptive.
BackgroundDepo-Provera is an injectable progestin contraceptive used by millions of women globally. Recent epidemiological studies linking long-term use to intracranial meningioma brain tumors sparked nationwide product liability lawsuits accusing Pfizer of failing to warn users.
- Lawsuits allege Pfizer failed to adequately warn patients and physicians about intracranial brain tumor risks associated with long-term contraceptive injections.
- Plaintiffs' counsel are preparing a petition to the Judicial Panel on Multidistrict Litigation to centralize federal cases before a single district judge.
- Growing case counts across federal district courts build momentum toward formal MDL consolidation, which could coordinate thousands of pending claims in 2027.
Mass Tort
Vehicles and medical devices lead product liability dockets — Lex Machina's report confirms MDL consolidations continue to absorb most federal injury claims.
BackgroundProduct liability litigation involves personal injury lawsuits filed against manufacturers over defective vehicles, pharmaceuticals, and medical devices. Federal multidistrict litigation consolidations centralize similar injury claims before single district judges to streamline pre-trial proceedings.
- Motor vehicle personal injury claims led total federal product liability filings, closely followed by medical device and pharmaceutical suits across active federal dockets.
- The annual report analyzed active federal judicial districts, high-volume plaintiff law firms, and defense law firm representation metrics to map litigation trends.
- Multidistrict litigation consolidations continue to represent the vast majority of pending federal product injury claims, driving overall court caseloads.
Mass Tort
Takeda and Zydus face a Prevacid class action — the suit ties price hikes directly to failure-to-warn kidney injury claims to maximize damages.
BackgroundProton pump inhibitors are widely used stomach acid reducers linked in litigation to chronic kidney disease and renal failure. Mass tort litigation against PPI manufacturers combines drug injury claims with consumer protection suits over unfair pricing tactics.
- The class action suit combines drug price increase allegations with failure-to-warn claims regarding long-term health risks, expanding legal risks beyond personal injury.
- Plaintiffs allege chronic use of Prevacid causes unwarned kidney damage, arguing patients paid inflated prices for drugs carrying undisclosed health dangers.
- The filing intersects with ongoing multidistrict mass tort litigation covering proton pump inhibitor medications across federal district courts.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
